Journal of Internal Medicine 1998; **243**: 595–599

Author index

Abdelnoor M *see* Reikvam Å *et al.*
Åberg H *see* Asplund R
Addolorato G *see* Capristo E *et al.*
Agarwal SK *see* Guru SC *et al.*
Agarwal SK *see* Marx SJ *et al.*
Ahrén B *see* Florén C-H *et al.*
Allemann J *see* Canova CR *et al.*
Anderson DR *see* Wells PS *et al.*
Ando M *see* Yoshimatsu S-I *et al.*
Ando Y *see* Yoshimatsu S-I *et al.*
Archimandritis A, Souyioultzis S, Katsorida M, Tzivras M. *Clostridium difficile* colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate *Helicobacter pylori* (Case report), 251
Argiris A *see* Gould D
Artner-Dworzak E *see* Samsonov M *et al.*
Asai N *see* Takahashi M *et al.*
Asplund R, Åberg H. Sleep and cardiac symptoms amongst women aged 40–64 years, 209

Bartosik J *see* Florén C-H *et al.*
Bävenholm P *see* Regnström J *et al.*
Beattie JR, Cohen DJ, Manning WJ, Douglas PS. Role of routine transthoracic echocardiography in evaluation and management of stroke, 281
Belenkov J *see* Samsonov M *et al.*
Bender BU *see* Neumann HPH
Bender R *see* Sawicki PT *et al.*
Bengtsson K *see* Bøg-Hansen E *et al.*
Bengtsson M *see* Florén C-H *et al.*
Berge RK *see* Nordoy A *et al.*
Bergenfelz A *see* Valdemarsson S *et al.*
Berger M *see* Sawicki PT *et al.*
Berger M *see* Sawicki PT
Berglin Blohm M, Hartford M, Karlsson T, Herlitz J. Factors associated with pre-hospital and in-hospital myocardial infarction: a 6-year experience, 243
Berglund G *see* Endre T *et al.*
Berntorp E, Berntorp K, Brorson H, Frick K. Liposuction in Dercum's disease: impact on haemostatic factors associated with cardiovascular disease and insulin sensitivity, 197
Berntorp K *see* Berntorp E *et al.*
Betsos N *see* Romeo G *et al.*
Bøg-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Råstam L. Risk factor clustering in patients with hypertension and non-insular-dependent diabetes mellitus (NIDDM). The Skaraborg Hypertension Project, 223
Boman K *see* Weinehall L *et al.*
Bønaa KH *see* Nordoy A *et al.*
Bonardi G *see* Romeo G *et al.*
Bredberg A *see* Sjöberg K *et al.*
Brorson H *see* Berntorp E *et al.*
Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1 (Minisymposium), 465

Cabeda JM *see* Cardoso EMP *et al.*
Cadiot G *see* Mignon M
Campello C *see* Richard S *et al.*
Canova CR, Kuhn M, Allemann J, Reinhart WH. Lethal pulmonary hypertension in a young woman caused by unrecognized haemangiosis carcinomatosa (Case report), 255
Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. Metabolic features of inflammatory bowel disease in a remission phase of the disease activity, 339
Cardoso EMP, Stål P, Hagen K, Cabeda JM, Esin S, De Sousa M, Hultcrantz R. *HFE* mutations in patients with hereditary haemochromatosis in Sweden, 203
Carlomagno F *see* Santoro M *et al.*
Carney JA. Familial multiple endocrine neoplasia syndromes: components, classification, and nomenclature (Minisymposium), 425
Ceccherini I *see* Romeo G *et al.*
Celli J *see* Romeo G *et al.*
Choo KE *see* Davis TME *et al.*
Chrousos GP, Stratakis CA. Carney complex and the familial lentiginosis syndromes: link to inherited neoplasias and developmental disorders, and genetic loci (Minisymposium), 573
Cieślar E *see* Hruby Z *et al.*
Cogo A *see* Wells PS *et al.*
Cohen DJ *see* Beattie JR *et al.*
Crabtree JS *see* Guru SC *et al.*

D'Ovidio R *see* Wells PS *et al.*
Dahlen GH *see* Weinehall L *et al.*
Davis TME, Singh B, Choo KE, Ibrahim J, Sulaiman SA, Kadir ZA, Ismail R. Dynamic assessment of parathyroid function in acute malaria, 349
de Faire U *see* Regnström J *et al.*
de Herder WW *see* Lamberts SWJ *et al.*
De Marzio P *see* Sgreccia A *et al.*
De Sousa M *see* Cardoso EMP *et al.*
De Vincentis G *see* Sgreccia A *et al.*
De Vita G *see* Santoro M *et al.*
Debelenko LV *see* Guru SC *et al.*
Debenedetti MK *see* Moley JF *et al.*
Dilley WG *see* Moley JF *et al.*
Douglas PS *see* Beattie JR *et al.*
Drory Y *see* Lev EI *et al.*
Dulawa J *see* Hruby Z *et al.*

Egermayer P. Hyperthyroidism and pulmonary hypertension (Letter to the Editor), 398
Ek P, Toomik R, Eriksson S, Frithz G, Ronquist G, Engström L. Erythrocytic protein kinase C activity in primary hypertension, 299
El-Salhy M, Simonsson M, Stenling R, Grimelius L. Recovery from Marie-Bamberger's syndrome and diabetes insipidus after removal of a lung adenocarcinoma with neuroendocrine features (Case report), 171
Emmert-Buck MR *see* Marx SJ *et al.*
Endre T, Mattiasson I, Berglund G, Hulthén UL. Muscle fibre composition and glycogen synthase activity in hypertension-prone men, 141
Engström L *see* Ek P *et al.*
Ericson M *see* Jensen-Urstad M *et al.*
Ericsson C-G *see* Regnström J *et al.*
Eriksson KF *see* Sjöberg K *et al.*

© 1998 Blackwell Science Ltd

Eriksson M, Hådell K, Holme I, Walldius G, Kjellström T. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care, 373
Eriksson S *see* Ek P *et al.*
Eriksson S *see* Sjöberg K *et al.*
Esin S *see* Cardoso EMP *et al.*

Faber J *see* Knudsen N *et al.*
Facchini FS *see* Jeppesen J *et al.*
Fellström B. Atherosclerosis: Usage and misusage (Reply to Letter to the Editor), 397
Ferrante L *see* Sgreccia A *et al.*
Filipowski H *see* Hruby Z *et al.*
Fisman EZ *see* Lev EI *et al.*
Florén C-H, Ahrén B, Bengtsson M, Bartosik J, Obrant K. Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine, 123
Forssmann W-G *see* Haller C *et al.*
Foster G *see* Wells PS *et al.*
Franzson L *see* Kristinsson JÖ *et al.*
Frick K *see* Berntorp E *et al.*
Friedman EH. Neurobiology of the association of chronic work stress with atherogenic lipids and elevated fibrinogen in middle-aged men (Letter to the Editor), 340
Frithz G *see* Ek P *et al.*
Fuchs D *see* Samsonov M *et al.*
Fusco A *see* Santoro M *et al.*

Gansevoort RT *see* van der Kleij FGH *et al.*
Gartaganis S *see* Georgiou S *et al.*
Gasbarrini G *see* Capristo E *et al.*
Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D. Efficacy and safety of systemic recombinant interferon-alpha in Behcet's disease, 367
Ginsberg JS *see* Wells PS *et al.*
Girolami A *see* Wells PS *et al.*
Goerz G *see* Georgiou S *et al.*
Goldfarb DA. Nephron-sparing surgery and renal transplantation in patients with renal cell carcinoma and von Hippel–Lindau disease (Minisymposium), 563
Golubrović E *see* Stefanović V *et al.*
Gould D, Argiris A. Unilateral breast oedema as a manifestation of congestive heart failure (Letter to the Editor), 328
Greco AV *see* Capristo E *et al.*
Greenaway TM *see* Burgess JR *et al.*
Grimelius L *see* El-Salhy M *et al.*
Grundy SM *see* Mostaza JM *et al.*
Gunji A *see* Yanagibori R *et al.*
Guru SC, Manickam P, Crabtree JS, Olufemi S-E, Agarwal SK, Debelenko LV *et al.*. Identification and characterization of the multiple endocrine neoplasia type 1 (*MEN1*) gene (Minisymposium), 433

Hådell K *see* Eriksson M *et al.*
Hagen K *see* Cardoso EMP *et al.*
Haller C, Meyer M, Scheele T, Koch A, Forssmann W-G, Kübler W. Radiocontrast-induced natriuresis associated with increased urinary urodilation excretion, 155
Hallmans G *see* Weinehall L *et al.*
Hamsten A *see* Regnström J *et al.*
Hanfland P *see* Harbrecht U *et al.*
Hansen J-B *see* Nørdoy A *et al.*
Harbrecht U, Oldenburg J, Klein P, Weber D, Rockstroh J, Hanfland P. Increased sensitivity of factor IX to phenprocoumon as a cause of bleeding in a patient with antiphospholipid antibody associated thrombosis (Case report), 73
Hartford M *see* Berglin Blohm M *et al.*
Harvey CJ, Johnston JD. Cardiopathia fantastica exposed by rapid sequential serum creatinine kinase analysis (Case report), 323
Hedblad B, Janzon L, Jungquist G, Ögren M. Factors modifying the prognosis in men with asymptomatic carotid artery disease, 57
Hegedüs L *see* Knudsen N *et al.*
Heitz PU *see* Komminoth P *et al.*
Hellenius M-L *see* Regnström J *et al.*
Henriksson P *see* Karlberg K-E *et al.*
Heppner C *see* Marx SJ *et al.*
Herlitz J *see* Berglin Blohm M *et al.*
Herlitz J *see* Kristinsson JÖ *et al.*
Herlitz J, Karlson BW, Lindqvist J, Sjölin M. Predictors and mode of death over 5 years amongst patients admitted to the emergency department with acute chest pain or other symptoms raising suspicion of acute myocardial infarction, 41
Hes FJ *see* Wittel-Post D *et al.*
Hirsh J *see* Wells PS *et al.*
Hirshberg B, Trelezky V, Raz I. Hypoglycaemia following pancreatic allograft transplantation (Case report), 389
Hofland LJ *see* Lamberts SWJ *et al.*
Holm G. Journal of Internal Medicine: a journal in progress (Editorial), 1
Holme I *see* Eriksson M *et al.*
Hölzl B, Paulweber B, Sandhofer F, Patsch JR. Hypertriglyceridemia and insulin resistance (Case report), 79
Hoogerbrugge N, Jansen H, De Heide L, Zillikens MC, Deckers JW, Birkenhäger JC. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia (Erratum), 403 (reprint from **241**:151–156.)
Hoogerbrugge N, Kerkhofs LGM, Jansen H. Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia, 355
Hruby Z, Smolska D, Filipowski H, Rabczyński J, Cieślar E, Kopeć W, Dulawa J. The importance of tubulointerstitial injury in the early phase of primary glomerular disease, 215
Huhtasaari F *see* Weinehall L *et al.*
Hultcrantz R *see* Cardoso EMP *et al.*
Hulthén UL *see* Endre T *et al.*

Ibrahim J *see* Davis TME *et al.*
Ikeda Y *see* Suga S *et al.*
Iliopoulos O *see* Kaelin WG *et al.*
Ingebretsen OC *see* Nørdoy A *et al.*
Intragumtornchai T, Rojnukkarin P, Swasdikul D, Israsena S. The role of serum ferritin in the diagnosis of iron deficiency anaemia in patients with liver cirrhosis, 233
Isamail R *see* Davis TME *et al.*
Israsena S *see* Intragumtornchai T *et al.*
Itakura H *see* Yanagibori R *et al.*
Ito S *see* Takahashi M *et al.*
Iwamoto T *see* Yanagibori R *et al.*
Iwashita T *see* Takahashi M *et al.*

Jäckel E *see* Tietge UJF *et al.*

Jackson CE. A 50 year perspective on endocrine neoplasia: clinic to genes and back (Minisymposium), 419
Jansen H *see* Hoogerbrugge N *et al.*
Jansson J-H *see* Weinehall L *et al.*
Janzon L *see* Hedblad B *et al.*
Jasonni V *see* Romeo G *et al.*
Jensen RT. Management of the Zollinger–Ellison syndrome in patients with multiple endocrine neoplasia type 1 (Minisymposium), 477
Jensen-Urstad K *see* Jensen-Urstad M *et al.*
Jensen-Urstad M, Jensen-Urstad K, Ericson M, Johansson J. Heart rate variability is related to leucocyte count in men and to blood lipoproteins in women in a healthy population of 35-year old subjects, 33
Jeppesen J, Facchini FS, Reaven GM. Individuals with high total cholesterol/HDL cholesterol ratios are insulin resistant, 293
Johansson J *see* Jensen-Urstad M *et al.*
Johnson O *see* Weinehall L *et al.*
Johnston JD *see* Harvey CJ
Jolobe OMP. Cardiac tamponade preceding adrenal insufficiency – an unusual presentation of Addison's disease (Letter to the Editor), 399
Jolobe OMP. *Chlamydia pneumoniae* (Letter to the Editor), 328
Jolobe OMP. Congestive heart failure in old age (Letter to the Editor), 327
Jovinge S *see* Regnström J *et al.*
Jungquist G *see* Hedblad B *et al.*

Kadir ZA *see* Davis TME *et al.*
Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M. Functions of the von Hippel–Lindau tumour suppressor protein (Minisymposium), 535
Karlberg K-E, Saldeen T, Wallin R, Henriksson P, Nyquist O, Sylvén C. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo-controlled study, 25
Karlson BW *see* Herlitz J *et al.*
Karlsson T *see* Berglin Blohm M *et al.*
Kasai N *see* Suga S *et al.*
Katsorida M *see* Archimandritis A *et al.*
Kawakubo K *see* Yanagibori R *et al.*
Kearon C *see* Wells PS *et al.*
Kerkhofs LGM *see* Hoogerbrugge N *et al.*
Kester MB *see* Marx SJ *et al.*
Kim YS *see* Marx SJ *et al.*
Kinpara I *see* Suga S *et al.*
Kiwitt S *see* Sawicki PT *et al.*
Kjellstrand CM, Kovithavongs C, Szabo E. On the success, cost and efficiency of modern medicine: an international comparison, 3
Kjellström T *see* Eriksson M *et al.*
Klein P *see* Harbrecht U *et al.*
Klöppel G *see* Komminoth P *et al.*
Knudsen N, Faber J, Sierbæk-Nielsen A, Vadstrup S, Sörensen HA, Hegedüs L. Thyroid hormone treatment aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women, 149
Koch A *see* Haller C *et al.*
Komminoth P, Heitz PU, Klöppel G. Pathology of MEN-1: morphology, clinicopathologic correlations and tumour development (Minisymposium), 455
Kondo K *see* Yanagibori R *et al.*
Kopeć W *see* Hruby Z *et al.*
Kovithavongs C *see* Kjellstrand CM *et al.*
Kreeftenberg HG *see* van der Kleij FGH *et al.*
Kristinsson JÖ, Valdimarsson Ö, Sigurdsson G, Franzson L, Olafsson I, Steingrimsdottir L, Herlitz J. Serum 25-hydroxyvitamin D levels and bone mineral density in 16–20-year-old girls: lack of association, 381
Kübler W *see* Haller C *et al.*
Kuhn M *see* Canova CR *et al.*

Lamberts SWJ, Hofland LJ, Lely AJVD, de Herder WW. Somatostatin receptor expression in multiple endocrine neoplasia and in von Hippel–Lindau disease (Minisymposium), 569
Lely AJVD *see* Lamberts SWJ *et al.*
Lensing AWA *see* Wells PS *et al.*
Lerone M *see* Romeo G *et al.*
Lev EI, Pines A, Drory Y, Rotmensch HH, Tenenbaum A, Fisman EZ. Exercise-induced aortic flow parameters in early postmenopausal women and middle-aged men, 275
Lindberg A *see* Sjohölm Å *et al.*
Lindblad U *see* Bøg-Hansen E *et al.*
Lindergård B *see* Valdemarsson S *et al.*
Lindqvist J *see* Herlitz J *et al.*
Lips CJM *see* Wittel-Post D *et al.*
Lips CJM. Clinical management of the multiple endocrine neoplasia syndromes: Results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and Von Hippel–Lindau Disease, 589
Lips CJM. Multiple endocrine neoplasia and von Hippel-Lindau disease (Minisymposium), 411
Löfmark R, Nilstun T. Informing patients and relatives about do-not-resuscitate decisions. Attitudes of cardiologists and nurses in Sweden, 191
Lonergan KM *see* Kaelin WG *et al.*
Lopatin J *see* Samsonov M *et al.*
Lupoli G *see* Santoro M *et al.*

Maher ER *see* Richards FM *et al.*
Manickam P *see* Guru SC *et al.*
Maniwa K *see* Yanagawa H *et al.*
Manning WJ *see* Beattie JR *et al.*
Manns MP *see* Tietge UJF *et al.*
Mareev V *see* Samsonov M *et al.*
Martucciello G *see* Romeo *et al.*
Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Emmert-Buck MR *et al.* Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (Minisymposium), 447
Mattiasson I *see* Endre T *et al.*
McMahon R *see* Richards FM *et al.*
Melander A *see* Bøg-Hansen E *et al.*
Melillo RM *see* Santoro M *et al.*
Meyer M *see* Haller C *et al.*
Mignon M, Cadiot G. Diagnostic and therapeutic criteria in patients with Zollinger–Ellison syndrome and multiple endocrine neoplasia type 1 (Minisymposium), 489
Mingrone G *see* Capristo E *et al.*
Mitić-Zlatković M *see* Stefanović V *et al.*
Miyata J *see* Yanagawa H *et al.*
Moley JF, DeBenedetti MK, Dilley WG, Tisell LE, Wells SA. Surgical management of patients with persistent or recurrent medullary thyroid cancer (Minisymposium) 521
Monastirli A *see* Georgiou S *et al.*

Morelli S *see* Sgreccia A *et al.*
Mostaza JM, Vega GL, Snell P, Grundy SM. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue, 265
Murakami H *see* Suga S *et al.*
Murakami H *see* Takahashi M *et al.*

Nassonov E *see* Samsonov M *et al.*
Neumann HPH, Bender BU. Genotype–phenotype correlations in von Hippel–Lindau disease (Minisymposium), 541
Nieminen MS *see* Rossinen J *et al.*
Nilsen H *see* Nørdoy *et al.*
Nilsson J *see* Regnström J *et al.*
Nilstun T *see* Löfmark R
Nørdoy A, Bønaa KH, Nilsen H, Berge RK, Hansen J-B, Ingebretsen OC *et al.*. Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia, 163
Nyquist O *see* Karlberg K-E *et al.*

Öberg K, Skogseid B. The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1 (Minisymposium), 471
Obrant K *see* Florén C-H *et al.*
Ögren M *see* Hedblad B *et al.*
Ogushi F *see* Yanagawa H *et al.*
Ohh M *see* Kaelin WG *et al.*
Olafsson I *see* Kristinsson JÖ *et al.*
Oldenburg J *see* Harbrecht U *et al.*
Olufemi S-E *see* Guru SC *et al.*
Onuma T *see* Suga S *et al.*

Parker F *see* Richards S *et al.*
Partanen J *see* Rossinen J *et al.*
Pasmatzi E *see* Georgiou S *et al.*
Patsch JR *see* Hölzl B *et al.*
Paulweber B *see* Hölzl B *et al.*
Pearson PL, Van der Luijt RB. The genetic analysis of cancer (Minisymposium), 413
Perrone C *see* Sgreccia A *et al.*
Personne M *see* Sjohölm Å *et al.*
Pines A *see* Lev EI *et al.*
Prandoni P *see* Wells PS *et al.*
Priolo M *see* Romeo G *et al.*

Rabczyński J *see* Hruby Z *et al.*
Ranstam J *see* Bøg-Hansen E *et al.*
Råstam L *see* Bøg-Hansen E *et al.*
Raz I *see* Hirshberg B *et al.*
Reaven GM *see* Jeppesen J *et al.*
Regnström J, Jovinge S, Båvenholm P, Ericsson C-G, de Faire U, Hamsten A, Hellenius M-L, Nilsson J, Tornvall P. *Helicobacter pylori* seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease, 109
Reikvam Å, Abdelnoor M, Sivertssen E. Has hospital mortality from acute myocardial infarction been markedly reduced since the introduction of thrombolytics and aspirin? 259
Reinhart WH *see* Canova CR *et al.*
Reitsma WD *see* van der Kleij FGH *et al.*
Resche F *see* Richard S *et al.*
Richard S, Campello C, Taillandier L, Parker F, Resche F. Haemangioblastoma of the central nervous system in von Hippel–Lindau disease (Minisymposium), 547
Richards FM, Webster AR, McMahon R, Woodward ER, Rose S, Maher ER. Molecular genetic analysis of von Hippel–Lindau disease (Minisymposium), 527
Rockstroh J *see* Harbrecht U *et al.*
Rojnukkarin P *see* Intragumtornchai T *et al.*
Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V, Martucciello G. Association of multiple endocrine neoplasia type 2 and Hirschprung disease (Minisymposium), 515
Ronquist G *see* Ek P *et al.*
Rose S *see* Richards FM *et al.*
Rossinen J, Partanen J, Stenius-Aarniala B, Nieminen MS. Salbutamol inhalation has no effect on myocardial ischaemia arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease, 361
Rotmensch HH *see* Lev EI *et al.*

Sakashita N *see* Yoshimatsu S-I *et al.*
Saldeen T *see* Karlberg K-E *et al.*
Salvatore G *see* Santoro M *et al.*
Samsonov M, Lopatin J, Tilz GP, Artner-Dworzak E, Nassonov E, Mareev V, Belenkov J, Wachter H, Fuchs D. The activated immune system and the renin–angiotensin–aldosterone system in congestive heart failure, 93
Sandhofer F *see* Hölzl B *et al.*
Santoro M, Melillo RM, Carlomagno F, Visconti R, De Vita G, Salvatore G, Lupoli G, Fusco A, Vecchio G. Molecular biology of the *MEN2* gene (Minisymposium), 505
Sawicki PT, Berger M. Pharmacological treatment of diabetic patients with cardiovascular complications (Review), 181
Sawicki PT, Kiwitt S, Bender R, Berger M. The value of QT interval dispersion for identification of total mortality risk in non-insulin-dependent diabetes mellitus, 49
Scheele T *see* Haller C *et al.*
Schmidt HH-J *see* Tietge UJF *et al.*
Scopinaro F *see* Sgreccia A *et al.*
Seri M *see* Romeo G *et al.*
Sgreccia A, Morelli S, Ferrante L, Perrone C, De Marzio P, De Vincentis G, Scopinaro F. QT interval and QT dispersion in systemic sclerosis (scleroderma), 127
Shepherd JJ *see* Burgess JR *et al.*
Sierbæk-Nielsen A *see* Knudsen N *et al.*
Sigurdsson G *see* Kristinsson JÖ *et al.*
Simonsson M *see* El-Salhy M *et al.*
Singh B *see* Davis TME *et al.*
Sivertssen E *see* Reikvam Å *et al.*
Sjöberg K, Eriksson KF, Bredberg A, Wassmuth R, Eriksson S. Screening for coeliac disease in adult insulin-dependent diabetes mellitus, 133
Sjohölm Å, Lindberg A, Personne M. Acute nutmeg intoxication (Letter to the Editor), 329
Sjölin M *see* Herlitz J *et al.*
Skogseid B *see* Öberg K
Smolsak D *see* Hruby Z *et al.*
Snell P *see* Mostaza JM *et al.*
Sone S *see* Yanagawa H *et al.*
Sörensen HA *see* Knudsen N *et al.*
Souyioultzis S *see* Archimandritis A *et al.*
Speich R *see* Thurnheer R

Stål P *see* Cardoso EMP *et al.*
Stefanović V, Golubrović E, Vlahović P, Mitić-Zlatković M. Age-related changes in IL-12 production by peripheral blood mononuclear cells (PBMC) (Letter to the Editor), 83
Stehbens WE. Atherosclerosis: Usage and misusage (Letter to the Editor), 395
Steingrimsdottir L *see* Kristinsson JÖ *et al.*
Stenius-Aarniala B *see* Rossinen J *et al.*
Stenling R *see* El-Salhy M *et al.*
Stratakis CA *see* Chrousos GP
Suda T *see* Suga S *et al.*
Suga M *see* Yoshimatsu S-I *et al.*
Suga S, Tamasawa N, Kinpara I, Murakami H, Kasai N, Onuma T, Ikeda Y, Takagi A, Suda T. Identification of homozygous lipoprotein lipase gene mutation in a woman with recurrent aggravation of hypertriglyceridaemia induced by pregnancy, (Case report) 317
Sulaiman SA *see* Davis TME *et al.*
Suzuki Y *see* Yanagawa H *et al.*
Suzuki Y *see* Yanagibori R *et al.*
Swasdikul D *see* Intragumtornchai T *et al.*
Sylvén C *see* Karlberg K-E *et al.*
Szabo E *see* Kjellstrand CM *et al.*

Tada S *see* Yoshimatsu S-I *et al.*
Taillandier L *see* Richard S *et al.*
Takagi A *see* Suga S *et al.*
Takahashi M, Asai N, Iwashita T, Murakami H, Ito S. Molecular mechanisms of development of multiple endocrine neoplasia 2 by *RET* mutations (Minisymposium), 509
Takeuchi E *see* Yanagawa H *et al.*
Tamasawa N *see* Suga S *et al.*
Tenenbaum A *see* Lev EI *et al.*
Terazaki H *see* Yoshimatsu S-I *et al.*
The European Consortium on *MEN-1*. The search for the *MEN1* gene (Minisymposium), 441
Theh BT. Thymic carcinoids in multiple endocrine neoplasia type 1 (Minisymposium), 501
Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger–Ellison syndrome, hypoglycaemia or both (Minisymposium), 495
Thurnheer R, Speich R. Hyperthyroidism and pulmonary hypertension (Reply to Letter to the Editor), 399
Tibblin S *see* Valdemarsson S *et al.*
Tietge UJF, Schmidt HH-J, Jäckel E, Trautwein C, Manns MP. Low molecular weight heparin-induced skin necrosis occurring distant from injection sites and without thrombocytopenia (Case report), 313
Tilz GP *see* Samsonov M *et al.*
Tisell LE *see* Moley JF *et al.*
Tonstad S. Do genetic determinates of ischaemic heart disease imply that prevention may become more difficult? (Review), 333
Toomik R *see* Ek P *et al.*
Torfoss D. Cardiac tamponade preceding adrenal insufficiency – an unusual presentation of Addison's disease (Reply to Letter to the Editor), 399
Tornvall P *see* Regnström J *et al.*
Trautwein C *see* Tietge UJF *et al.*
Trelizky V *see* Hirshberg B *et al.*
Tsambaos D *see* Georgiou S *et al.*
Tzivras M *see* Archimandritis A *et al.*

Uchino M *see* Yoshimatsu S-I *et al.*

Vadstrup S *see* Knudsen N *et al.*
Valdemarsson S, Lindergård B, Tibblin S, Bergenfelz A. Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease, 115
Valdimarsson Ö *see* Kristinsson JÖ *et al.*
van Dalen A *see* van Vroonhoven Th JMV
van der Kleij FGH, Gansevoort RT, Kreeftenberg HG, Reitsma WD. Imported rickettsioses: think of murine typhus (Case report), 177
Van der Luijt RB *see* Pearson PL
van Vroonhoven Th JMV, van Dalen A. Successful minimally invasive surgery in primary hyperparathyroidism after combined preoperative ultrasound and computed tomography imaging (Minisymposium), 581
Vecchio G *see* Santoro M *et al.*
Vega GL *see* Mostaza JM *et al.*
Visconti R *see* Santoro M *et al.*
Vlahović P *see* Stefanović V *et al.*

Wachter H *see* Samsonov M *et al.*
Wall S *see* Weinhall L *et al.*
Walldius G *see* Eriksson M *et al.*
Wallin R *see* Karlberg K-E *et al.*
Wassmuth R *see* Sjöberg K *et al.*
Weber D *see* Harbrecht U *et al.*
Webster AR *see* Richards FM *et al.*
Weinehall L, Johnson O, Jansson J-H, Boman K, Huhtasaari F, Hallmans G, Dahlen GH, Wall S. Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case-control study from northern Sweden, 99
Weitz J *see* Wells PS *et al.*
Wells PS, Hirsh J, Anderson DR, Lensing AWA, Foster G, Kearon C, Weitz J, D'Ovidio R, Cogo A, Prandoni P, Girolami A, Ginsberg JS. A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: the potential for an improvement in the diagnostic process, 15
Wells SA *see* Moley JF *et al.*
Werdan K. The activated immune system in congestive heart failure – from dropsy to the cytokine paradigm (Editorial), 87
Wittebol-Post D, Hes FJ, Lips CJM. The eye in von Hippel–Lindau disease. Long-term follow-up of screening and treatment: recommendations (Minisymposium), 555
Woodward ER *see* Richards FM *et al.*

Yamashita T *see* Yoshimatsu S-I *et al.*
Yanagawa H, Takeuchi E, Miyata J, Maniwa K, Suzuki Y, Ogushi F, Sone S. Rheumatoid plerual effusion with detectable level of interleukin-15 (Letter to the Editor), 331
Yanagibori R, Kondo K, Suzuki Y, Kawakubo K, Iwamoto T, Itakura H, Gunji A. Effect of 20 days' bed rest on the reverse cholesterol transport system in healthy young subjects, 307
Yin L *see* Romeo G *et al.*
Yoshimatsu S-I, Ando Y, Terazaki H, Sakashita N, Tada S, Yamashita T, Suga M, Uchino M, Ando M. Endoscopic and pathological manifestations of the gastrointestinal tract in familial amyloidotic polyneuropathy type I (Met 30), 65

Journal of Internal Medicine 1998; **243**: 601–603

Keyword index

acute chest pain, 41
acute myocardial infarction, 99, 243
acute phase reactant, 109
adenocarcinoma, 171
adolescents, 381
adrenal, 465
AL amyloidosis, 65
aldosterone, 93
amyloid, 65
anaemia, 233
angina pectoris, 25
angiotensin, 93
anticoagulation, 281
antiduretic hormone, 171
antihypertensive treatment, 181
antiphospholipid antibody syndrome, 73
aortic flow, 275
aphthae, 367
aspirin treatment, 259
asthma, 361
azathioprine, 123

bed rest, 307
Behcet's disease, 367
biomedical risk factors, 99
bone formation, 115
bone metabolism, 149
bone mineral density, 123, 381

calcium intake, 381
cancer genetics, 413
cardiac mortality, 49
cardiopathia fantastica, 323
cardiovascular disease, 181
cardiovascular risk factors, 33
carotid artery, 57
cerebrovascular mortality, 49
cholesterol ester transfer protein, 307
cholesterol, 293, 373
cholesterol-HDL ratio, 293
cholestyramine, 373
chronic obstructive pulmonary disease, 361
citrate clamp, 349
clarithromycin, 251
clinical management, 581
Clostridium difficile, 251
clustering, 223
coeliac disease, 133
colitis, 251
combined hyperlipidemia, 163
compliance, 373
computerized opinion poll, 581
congestive heart failure, 93
coronary angiography, 109, 155
coronary artery disease, 109, 361
corticosteroids, 123
Crohn's disease, 123, 339

delay, 243
Dercum's disease, 197
diabetes insipidus, 171
diabetes mellitus, 133, 181
diagnostic tests, 233
diarrhoea, 251
digestive endocrine tumours, 489
DNA repair genes, 413
do-not-resuscitate orders, 191
Doppler, 275
dual-energy X-ray absorptiometry (DEXA), 381
duodenal ulcer, 251

echocardiography, 281
economy, 3
elongins, 535
endocrine, 425
endomysial antibodies, 133
enteropancreatic, 465
erythrocyte, 299
euglycemic clamp technique, 141
exercise, 275
expenses, 3

factor IX, 73
familial MEN syndromes, 425
family history of hypertension, 141
FAP, 65
fat weight, 265
fatty acids, 265
fibrinogen, 197

gastrointestinal tract, 65
gemfibrozil, 355
genetics, 419
genotype, 203
genotype–phenotype correlations, 541
gliadin antibodies, 133
glomerulopathy, 215
glycogen synthase, 141
goitre, 149
gross domestic product, 3

haemochromatosis, 203
HDL-cholesterol, 265, 293, 307
heart disease, 323
heart rate variability, 33, 127, 361
Helicobacter pylori eradication therapy, 251
Helicobacter pylori, 109
heparin, 313
hereditary cancer, 413
hereditary tumour syndromes, 541
HFE, 203
hospital mortality, 259
human, 155
hyperparathyroidism, 419, 465
hypertension, 223, 299
hypertriglyceridemia, 79, 317
hypocalcaemia, 349, 389

IDDM, 133

© 1998 Blackwell Science Ltd

immune activation, 93
impedance plethysmography, 15
inflammation, 109
inflammatory bowel disease, 339
information, 191
inherited disorders, 203
insulin resistance, 79, 141, 265, 293
insulin sensitivity, 197
interferon-α, 367
interstitial morphometry, 215
iron deficiency, 233
iron, 203
irregular heart beat, 209

LDL cholesterol, 293
LDL size, 355
lecithin-cholesterol acyltransferase, 307
life expectancy, 3
lipid peroxides, 163
lipid-lowering, 373
lipoprotein lipase deficiency, 79, 317
lipoprotein lipase, 307
liposuction, 197
liver cirrhosis, 233
long-term prognosis, 41
lung, 171

malaria, 349
Marie-Bamberger's syndrome, 171
MEN-1, 465, 489
metronidazole, 251
mortality, 3, 41
multiple endocrine neoplasia, 419, 569, 581
multistep process, 413
Munchausen's syndrome, 323
murine typhus, 177
muscle fibre type, 141
myocardial infarction, 259, 323
myocardial ischaemia, 361

natriuretic peptides, 155
necrosis, 313
nephropathy, 181
nested case-control study, 99
neuroendocrine differentiation, 171
neurofibromatosis, 425
NIDDM, 223
nightmare, 209
nitroglycerin, 25
nocturnal awakening, 209
non-insulin-dependent diabetes mellitus, 49
nurses, 191

omega-3 fatty acids, 163
oral anticoagulant therapy, 73
oral antidiabetic agents, 181
osteocalcin, 115
outcome, 3
oxidation, 355

PAI-1, 197
pancreatic transplantation, 389
pancreatitis, 317
parathormone, 349
parathyroid hormone, 115
patients, 191
perceived health, 99
phakomatoses, 425
phenprocoumon, 73
phlebography, 15
physicians, 191
pituitary, 465
placebo-controlled, 25
platelets, 25
population study, 33
post-menopausal, 275
pravastatin, 373
prednisolone, 123
pregnancy, 317
prevalence, 133
primary health care, 223
primary hyperparathyroidism, 115, 489
primary-care, 373
protein kinase C, 299
proto-oncogenes, 413
pulmonary artery hypertension, 255
pulmonary embolism, 255

QT interval, 49, 127

radiocontrast, 155
relatives, 191
renin, 93
Rickettsia typhii, 177
rickettsioses, 177
risk factors, 41, 49, 223

Saccharomyces boulardii, 251
salbutamol, 361
screening, 465
secondary amyloidosis, 65
serum ferritin, 233
serum lipids, 163
sex, 373
side effects, 313
Simvastatin, 163
skeletal disease, 115
skin, 313
sleep, 209
smoking, 181
somatostatin receptors, 569
spasmodic chest pain, 209
stroke, 281
substrate oxidation, 339
systemic sclerosis, 127

thrombolytic therapy, 243
thrombolytic treatment, 259
thrombophlebitis, 15
thrombosis, 15
thyroid hormones, 149
total mortality, 49
transthyretin, 65
treatment goals, 223

triglyceride, 307, 355
triglycerides, 265
tubular function, 215
tubulointerstitium, 215
tumour embolism, 255
tumour suppressor gene, 535
tumour suppressor genes, 413
tumour suppressor protein, 535

ulcerative colitis, 339
ultra-levure, 251
ultrasound, 57, 149

Vitamin D, 381
Vitamin D-receptor genotypes (VDR), 381
VLDL-apo B, 265
von Hippel–Lindau disease, 425, 535, 541, 569, 581
VWF:Ag, 197

woman, 209

Zollinger–Ellison syndrome, 489